NCT07125521 Evaluating Medication Adherence of Patients With Gastroesophageal Reflux Disease With Support of the Smartphone Application GERDCare
| NCT ID | NCT07125521 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Institute of Gastroenterology and Hepatology, Vietnam |
| Condition | GERD (Gastroesophageal Reflux Disease) |
| Study Type | INTERVENTIONAL |
| Enrollment | 380 participants |
| Start Date | 2025-08-18 |
| Primary Completion | 2026-07-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 380 participants in total. It began in 2025-08-18 with a primary completion date of 2026-07-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Adherence to GERD treatment, including medication, diet, and lifestyle, is essential for symptom control and complication prevention, yet adherence rates remain low due to various demographic and clinical factors. Digital therapeutics, particularly mobile health applications, have shown promising potential in supporting chronic disease management and improving patient outcomes. The GERDCare mobile application was developed with direct input from gastrointestinal experts. It is designed to enhance treatment adherence and patient engagement by offering features such as educational resources, symptom tracking, medication reminders, and direct communication between patients and physicians. The investigators are conducting a single-center, open-label, randomized controlled trial to evaluate the effectiveness of using GERDCare in improving patient adherence. Patients are followed up after four weeks of GERD treatment.
Eligibility Criteria
Inclusion Criteria: * ≥18 years old * Presents with typical GERD symptoms (regurgitation, heartburn) * Owns a smartphone and capable of using smartphone applications. Exclusion Criteria: * Acute GI conditions (upper GI bleeding, acute peptic ulcer…) * GI malignancy (esophageal cancer, gastric cancer…) * Severe chronic comorbidities (heart failure, liver failure, chronic kidney disease…) * Pregnancy, alcohol abuse, mental health conditions impacting medication adherence or app usage
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07125521 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying GERD (Gastroesophageal Reflux Disease). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07125521 currently recruiting?
Yes, NCT07125521 is actively recruiting participants. Contact the research team at binhnguyen.fsh@gmail.com for enrollment information.
Where is the NCT07125521 trial being conducted?
This trial is being conducted at Hanoi, Vietnam.
Who is sponsoring the NCT07125521 clinical trial?
NCT07125521 is sponsored by Institute of Gastroenterology and Hepatology, Vietnam. The trial plans to enroll 380 participants.